Cetera Trust Company N.A Has $121,000 Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Cetera Trust Company N.A grew its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 30.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,210 shares of the company’s stock after buying an additional 1,665 shares during the quarter. Cetera Trust Company N.A’s holdings in Progyny were worth $121,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in PGNY. Vanguard Group Inc. grew its stake in shares of Progyny by 0.5% during the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock valued at $317,097,000 after purchasing an additional 41,687 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Progyny by 2.7% during the first quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock valued at $99,054,000 after purchasing an additional 67,632 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Progyny by 120.8% during the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Progyny by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock valued at $36,676,000 after acquiring an additional 254,725 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its stake in Progyny by 8.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 843,829 shares of the company’s stock valued at $24,142,000 after acquiring an additional 63,795 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of Progyny in a report on Tuesday, October 1st. BTIG Research lowered shares of Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Canaccord Genuity Group cut their target price on shares of Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a report on Friday, September 20th. Truist Financial cut their target price on shares of Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, September 19th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, September 19th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Progyny has an average rating of “Hold” and an average target price of $27.73.

Progyny Stock Performance

Progyny stock traded down $0.10 during mid-day trading on Tuesday, reaching $16.25. The company’s stock had a trading volume of 232,546 shares, compared to its average volume of 1,369,270. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 1.48 and a beta of 1.43. Progyny, Inc. has a 12 month low of $13.93 and a 12 month high of $42.08. The business’s 50 day simple moving average is $19.76 and its 200 day simple moving average is $25.62.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, meeting analysts’ consensus estimates of $0.17. The company had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.15 EPS. As a group, sell-side analysts expect that Progyny, Inc. will post 0.64 EPS for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.